跳到正文
Ingo Hartung· @HartungIngo · X·· 2026-04-20评分60

TRI-611

解读

小分子药物化学 — CDK2、WEE1、SERD(非 KRAS)

TRI-611 · 会场出现的早期编号

正文 · 原文

The 2nd oxadiazole-containing CRBN-dependent molecular glue degrader at #AACR26 today. Triana‘s CNS penetrating oral ALK degrader TRI-611 does not touch ALK‘s ATP binding site & utilizes a novel helical degron for CRBN hijacking leading to high degrader selectivity.

热度 62 · 53 赞 · 2 回复 · 7 转发

会议摘要
4618按 代号 TRI-611 对上
TRI-611, a development stage molecular glue degrader of ALK for the treatment of ALK-positive NSCLC including central nervous system metastases

Andrew R. Conery, Daniel S. La, Artyom A. Alekseyenko, David Marcoux, Aaron G. Bart, Matt L. Harlow, Patrick R. Arsenault, Nico R. Cantone, Rebecca L. Casaubon, Hari B. Kamadurai, Aravind Prasad Medikonda, Duncan E. Nunes, Tim J. Wigle, Maolin Yu, Aleksandra Zagulyaeva, Christine Zarate, Kathleen I. Seyb, Patrick Trojer, Vito J. Palombella

读摘要原文 →
5787按 代号 TRI-611 对上
TRI-611, a development stage molecular glue degrader of ALK, promotes the degradation of TKI-resistant ALK fusion proteins and leads to regression of ALK TKI-refractory tumors

Andrew R. Conery, Daniel S. La, Artyom A. Alekseyenko, David Marcoux, Aaron G. Bart, Matt L. Harlow, Patrick R. Arsenault, Nico R. Cantone, Rebecca L. Casaubon, Hari B. Kamadurai, Aravind Prasad Medikonda, Duncan E. Nunes, Tim J. Wigle, Maolin Yu, Aleksandra Zagulyaeva, Christine Zarate, Lauren Highfield, Nobuyuki Kondo, Aaron N. Hata, Kenneth Ngo, Jisu Lee, Prafulla C. Gokhale, Kathleen I. Seyb, Patrick Trojer, Vito J. Palombella

读摘要原文 →

来源:Ingo Hartung · x.com

CBACBA Frontier Insights (CFI)美国华人生物医药科技协会(CBA)www.cba-usa.org